Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Jefferies Virtual Healthcare Conference 2020
28 slides from Matinas Biopharma's conference presentation, Jun 2, 2020
Slide 1: Jefferies Virtual Healthcare Conference
MATINAS BIOPHARMA Jefferies Virtual Healthcare Conference June 2, 2020
Slide 2: Forward-looking statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive
Slide 3: Matinas Company Overview
Matinas Company Overview MAT9001 Potential Best-in-Class Omega-3 Drug = Potential best-in-class drug focused on severe hypertriglyceridemia with potential expansion into multi- billion dollar market = Head-to-head data demonstrating superior triglyceride lowering and EPA levels against leading drug,
Slide 4: Key upcoming milestones support investment thesis
Key upcoming milestones support investment thesis MAT9001 Potential Best-in-Class Omega-3 Drug LNC PLATFORM Lipid Nano-Crystal Delivery System June 2020: Resume head-to-head ENHANCE-IT study Q3 2020: End-of-Phase 2 meetings with FDA Q1 2021: Top-line data from ENHANCE-IT study H1 2021: Commence Phas
Slide 5: MAT9001 Overview
MAT9001 OVERVIEW MATINAS BIOPHARMA
Slide 6: MAT9001 is targeting a large market opportunity
MAT9001 is targeting a large market opportunity US Adult Prevalence, Calculated*, 2020 Hypertriglyceridemia 62,750,000 = SHTG patients have low rates of pharmacologic intervention = Primary treatment goal is reduction of | | Pp triglycerides Borderli igh (HTG: igh (HTG: S SHTG' geet oe a * MAT9001 d
Slide 7: Severe Hypertriglyceridemia: A Serious Problem
Severe Hypertriglyceridemia: A Serious Problem Incidence of clinical events in SHTG Patients by level of TG achieved Approximately 3.5 to 4 million adults in the United States have (n=41,210) severe hypertriglyceridemia (SHTG, 2500 mg/dL). 7 m< 200 Risk factors associated with severe hypertriglyceri
Slide 8: The MAT9001 Difference
The MAT9001 Difference _ OMEGA-3 BENEFITS Prescription Omega-3s offer a rare combination of potency, safety, and affordability Substantial benefits for both patients AND the US healthcare system Potential multi-billion-dollar market in the US (approval of Vascepa to treat patients at CV risk with TG
Slide 9: Formulated to achieve best-in-class potency
Formulated to achieve best-in-class potency Less Bioavailable Highly Bioavailable ETHYL ESTHERS 2 e FREE FATTY ACIDS ————————* LOVAZA ° Vascepa'* Epanova'&* MAT9001" DPA OTHER e 18T GENERATION ° @— 2N2 GENERATION —e Repurposed Products For CV Applications MATINAS BIOPHARMA
Slide 10: Demonstrated superiority head-to-head vs. Vascepa
Demonstrated superiority head-to-head vs. Vascepa® TRIGLYCERIDE REDUCTION MEDIAN % CHANGES FROM MEDIAN % CHANGES FROM PRE-TREATMENT (MEDIAN % CHANGE FROM BASELINE) PRE-TREATMENT VALUES FOR LIPIDS FOR APOLIPOPROTEINS AND PCSK9 a Non-HDL-C HDLC DLC’? = TC Apo B Apo AP Apo Clll PCsk92 4s 3% 10 10% 1 24
Slide 11: Substantially higher EPA blood levels vs. Vascepa
Substantially higher EPA blood levels vs. Vascepa® MEAN PLASMA BASELINE-ADJUSTED TOTAL EPA CONCENTRATION ON FINAL DAY OF TREATMENT! 350 —@— MAT9001 —@- Vascepa® 300 250 200 150 Plasma Baseline-Adjusted Total EPA (g/mL) 50 o 1 2 3 4&4 5 6 7 8 9 MN 2 13 % 1% 16 17 1 19 20 21 2 23 2% Time (Hours) from
Slide 12: MAT9001 Clinical Development Plan
MAT9001 CLINICAL DEVELOPMENT PLAN MATINAS BIOPHARMA
Slide 13: The path to significant market share
The path to significant market share REGISTRATION STUDIES v 28-day tox study v 90-day tox study 2 v Phase 1 PK vs Lovaza 7 = Single dose comparative bioavailability (n=36) im O Phase 3 Pivotal in SHTG (TG 500-2000 mg/dL) = MAT9001 (2g and 4g) vs placebo in SHTG > patients ‘i = Dosing in early 2021 =
Slide 14: ENHANCE-IT study: MAT9001 vs Vascepa
14 ENHANCE-IT study: MAT9001 vs Vascepa® OBJECTIVES To assess PD effects of MAT9001, compared with Vascepa®, on TGs and other lipoprotein lipids, apolipoproteins, hs-CRP, and PCSK@Q in men and women with elevated TGs = Randomized, open-label, active-control crossover design (n=100) = MAT9001 vs. Vas
Slide 15: IND Reactivation to NDA
IND Reactivation ¢ 48 MATINAS BIOPHARMA NDA
Slide 16: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio PATENT APPLICATIONS Additional IP to be developed as clinical development plan progresses. ORANGE BOOK-LISTABLE U.S. PATENTS ISSUED, EXTEND TO 2033 Q4 2014: US Patent No. 8,906,964 Q3 2018: US Patent No. 10,058,521 4 additional U.S. patent applications pendi
Slide 17: MAT2203 Overview
MAT2203 OVERVIEW MATINAS BIOPHARMA
Slide 18: Invasive fungal infections represent an urgent growing global need
Invasive fungal infections represent an urgent growing global need Global Invasive fungal infection market value in 2018 Potential for significant Amphotericin B market expansion Global Amphotericin B sales in. 2018 ~$6B The COVID-19 pandemic has shifted the spotlight onto infectious disease drug de
Slide 19: MAT2203: A novel approach with a proven therapeutic
MAT2203: A novel approach with a proven therapeutic MAT2203 \ LEVERAGES PLATFORM BIG POTENTIAL 19 Oral, encochleated Amphotericin B Being developed with support from the NIH Proprietary formulation with robust intellectual property protection Potential to expand use into larger prophylaxis and maint
Slide 20: EnACT Study: Encochleated Oral Amphotericin for Cryptococcal Meningitis
EnACT Study: Encochleated Oral Amphotericin for Cryptococcal Meningitis RATIONALE Traditional Amphotericin B deoxycholate given intravenously (IV AMB) has common and substantial toxicities that force switching. Anovel oral formulation of amphotericin has oral bioavailability, efficacy in animal mode
Slide 21: EnACT: Phase 2 in HIV patients with Cryptococcal Meningitis
EnACT: Phase 2 in HIV patients with Cryptococcal Meningitis INDUCTION THERAPY EARLY MAINTENANCE THERAPY (2 WEEKS) WIMAT2203 (4 WEEKS) Stage 1 IV Ampho rn n=10 5 days Stage 2 IV Ampho MAT: n=40 2 days " cecescrccsscn= Ly Stage 3 = re n=i0 | IV Ampho: 9 days MA y l ’ y Stage 4 | MV 4\ n=40 1 » » : 1 9
Slide 22: Lipid Nanocrystal (LNC) Platform
LIPID NANOCRYSTAL (LNC) PLATFORM MATINAS BIOPHARMA
Slide 23: LNC platform enables flexible, safe, targeted delivery of potent medicines
LNC platform enables flexible, safe, targeted delivery of potent medicines Matinas’ LNC Platform utilizes a highly efficient, physiologic and non-toxic drug formulation: FLEXIBLE ADMINISTRATION ~ = No evidence of immunogenicity = Oral = Intravenous = Reduced toxicity of drugs = Intramuscular = Intra
Slide 24: MAT2501: A better Amikacin
MAT2501: A better Amikacin 24 MAT2501 IMPROVED PROFILE _ | LEVERAGES _) PLATFORM Oral, encochleated Amikacin Initial target indication in non-tuberculosis mycobacterium (NTM) infections Proprietary formulation with robust intellectual property protection Development contingent on continued support f
Slide 25: Driving opportunities for value-added partnerships
Driving opportunities for value-added partnerships. 25 Viiv Genentech A Member of the Roche Group We are currently working with multiple strategic and research partners to expand potential successful applications of this LNC technology. In early 2019, we collaborated with a top global pharmaceutical
Slide 26: Upcoming Key Milestones
Upcoming Key Milestones MAT9001 MAT2203 LNC PLATFOR S iesdime need o eae = Resume Phase 2 portion of ENHANCE-IT study EnACT study = Partnership development * End-of-Phase 2 meeting with FDA» EnACT cohort progression updates ® Top-line data from ENHANCE-IT updates e lees grant decision from study = T
Slide 27: Matinas is led by a team of industry experts
Matinas is led by a team of industry experts EXECUTIVE OFFICERS Jerome D. Jabbour i: Co-Founder, Chief Executive Officer Reliant Keith A. Kucinski, CPA, MBA Chief Financial Officer IPB b Raphael J. Mannino, Ph.D. = Chief Scientific Officer RUDGERS sway _Dlodelivery James J. Ferguson Ill, M.D., FACC,
Slide 28: Matinas BioPharma
MATINAS BIOPHARMA Jefferies Virtual Healthcare Conference June — 2020
Matinas BioPharma Holdings — Jefferies Virtual Healthcare Conference 2020 on 6ix